** Shares of medical equipment maker Revvity fall ~1.6% to $119.05 premarket
** The company expects annual revenue between $2.75 bln and $2.77 bln, down from its previous forecast of $2.77 bln to $2.79 bln
** Q3 revenue from RVTY's Life Sciences segment was $301 mln, missing analysts' expectation of $306.15 mln - data compiled by LSEG
** It reports Q3 adjusted profit of $1.28/share vs analysts' average estimate of $1.13/share
** Favorable margins and lower tax rate enabled the profit beat - TD Cowen analysts
** Up to last close, stock up 10.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。